QC
RARE icon

Quadrature Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Quadrature Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Sell
52,746
-3,844
-7% -$95.5K 0.02% 550
2026
Q1 		$1.19M Sell
56,590
-9,411
-14% -$212K 0.01% 514
2025
Q4 		$1.52M Buy
+66,001
New +$2.17M 0.02% 418
2025
Q3 		– Sell
-13,944
Closed -$507K – 1417
2025
Q2 		$507K Buy
+13,944
New +$503K 0.01% 570

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Quadrature Capital's RARE Position: Q2 2026 in Review

Quadrature Capital reduced its Ultragenyx Pharmaceutical (RARE) stake by 6.8% in Q2 2026, selling an estimated $95.5K and leaving 52,746 shares worth $1.76M. The position accounts for 0.02% of the portfolio, ranked #550.

Quadrature Capital first reported a position in RARE in Q2 2025 and has held it in 4 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Quadrature Capital held 52,746 shares of Ultragenyx Pharmaceutical worth $1.76M as of Q2 2026.
  • Quadrature Capital sold 3,844 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $95.5K.
  • Ultragenyx Pharmaceutical made up 0.02% of Quadrature Capital's portfolio in Q2 2026, its #550 holding.
  • Quadrature Capital first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.